Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ

Antiviral Research

Volumn 29, Issue 2-3, 1996, Pages 199-207

  Saravolac, E G ^a   Kournikakis, B ^a   Gorton, L ^a   Wong, J P ^a  

^a CFB Suffield   (Canada)

Author keywords

influenza infection; interferon ; liposomes; macrophage

Indexed keywords

CHOLESTEROL; LIPOSOME; MURAMYL DIPEPTIDE; NITRIC OXIDE; NITRITE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; RECOMBINANT GAMMA INTERFERON; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG RETENTION; ENCAPSULATION; FEMALE; IMMUNOMODULATION; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTECTION; SURVIVAL RATE;

EID: 0029878986     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00832-2     Document Type: Article

References (37)

1. Bino, T., Madar, Z., Gertier, A. and Rosenberg, H. (1982) The kidney is the main site of interferon degradation. J. Interferon Res. 2, 301-308.
2. Corradin, S.B., Buchmüller-Rouiller, Y. and Manuel, J. (1991) Phagocytosis enhances murine macrophage activation by interferon-γ and tumor necrosis factor-α. Eur. J. Immunol. 21, 2553-2558.
3. Ding, A.H., Nathan, C.F. and Stuehr, D.J. (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages; comparison of activating cytokines and evidence for independant production. J. Immunol. 141, 2407-2412.
4. Douglas, R.M., Albrecht, J.K., Miles, H.B., Moore, B.W., Read, R., Worswick, D.A. and Woodward, A.J. (1985) Intranasal interferon-α2 prophylaxis of natural respiratory virus infection. J. Infect. Dis. 151, 731-736.
5. Dulbecco, R., and Ginsburg, H.S. (1980) The nature of viruses. In: B.D. Davis, R. Dulbeco, N.H. Eisen and H. S. Ginsburg (Eds.), Microbiology, 3rd ed., Harper and Row, Phildelphia, PA, pp. 854-884.
6. Eisen, N.H. (1980) Immunology, 2nd ed., Harper and Row, Philadelphia, PA, pp. 382-418.
7. Fidler, I.J. (1988) Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv. Drug Deliv. Rev. 2, 69.
8. Fidler, I.J., Raz, A., Fogler, W.E., Kirsch, R., Bugelski, P. and Post, G. (1980) Design of liposomes to improve delivery of macrophage augmenting agents to alveolar macrophages. Cancer Res. 40, 4460-4466.
9. Fidler, I.J., Fogler, W.E., Kleinerman, E.S. and Saiki, I. (1985) Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-γ encapsulated in liposomes. J. Immunol. 135, 4289-4296.
10. Fortier, A.H., Polsinelli, T., Green, S.J. and Nacy, C.A. (1992) Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells and effector molecules. Infect. Immunol. 60, 817-825.
11. 15N]nitrate in biological fluids. Anal. Biochem. 126, 131-138.
12. Green, S.J. and Nacy, C.A. (1993) Antimicrobial and immunopathologic effects of cytokine-induced nitric oxide synthesis. Curr. Opin. Inf. Dis. 6, 384-396.
13. Gregoriadis, G. (1990) Immunological adjuvants: a role for liposomes. Immunol. Today 11, 89-97.
14. Gutterman, J.U., Rosenblum, M.G., Rios, A.A., Herbert, A.F. and Quesada, J. (1984) Pharmacokinetic study of partially pure gamma interferon in cancer patients. Cancer Res. 44, 4164-4171.
15. 2 for prevention of rhinovirus infection and illness. J. Infect. Dis. 148, 543-550.
16. Higgins, P.G., Phillpotts, R.J., Scott, G.M., Wallace, J., Bernhardt, L.L. and Tyrrell, D.A.J. (1983) Intranasal interferon as protection against experimental respiratory coronavirus infections in volunteers. Antimicrob. Agents Chemother. 24, 713-715.
17. Hockertz, S., Franke, G., Paulini, I., Lohmann-Matthes, M.L. (1991) Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-γ and MTP-PE encapsulated in liposomes. J. Interferon Res. 11, 177-185.
18. Joklik, W.K. (1990) Interferons. In: B.N. Fields, D.M. Knipe et al., (Eds.), Virology, 2nd ed., Raven Press, New York, pp. 383-410.
19. Karupiah, G., Xie, Q.-W., Buller, M.L., Nathan, C., Duarte, C. and MacMicking (1993) Inhibition of viral replication by interferon-γ-induced nitric oxide synthase. Science 261, 1445-1448.
20. Killion, J.J. and Fidler, I.J. (1993) Liposome-encapsulated interferon alpha: a model for receptor-independent delivery of growth-inhibitory peptides. In: G. Gregoriadis (Ed.), Liposome Technology, Vol. II, CRC Press, Boca Raton, pp. 105-115.
21. Kirby, J.K. and Gregoriadis, G. (1984) A simple procedure for preparing liposomes capable of high efficiency under mild conditions. In: G. Gregoriadis (Ed.), Liposome Technology, Vol. I, CRC Press, Boca Raton, pp. 19-27.
22. Kurzrock, R., Rosenblum, M.G., Sherwin, S.A., Rios, A., Talpaz, M., Quesada, J.R. and Gutterman, J.U. (1985) Pharmacokinetics, single-dose tolerance, and biological activity of recombinant γ-interferon in cancer patients. Cancer Res. 45, 2866-2872.
23. Melissen, P.M.B., van Vianen, W., Bidjai, O., van Marion, M. and Bakker-Woudenberg, I.A.J.M. (1993) Free and liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (MTPPE) and interferon-γ in experimental infection with Listeria monocytogenes. Biotherapy 6, 113-124.
24. Merigan, T.C. (1987) Is recombinant interleukin-2 the best way to deliver interferon-gamma in human disease. J. Interferon Res. 7, 635-639.
25. Mischell, B.B. and Shiigi, S. (1980) Normal peritoneal cells. In: B.B. Mischell and S.M. Shiigi (Eds.), Selected Methods in Cellular Immunology, W.H. Freeman and Company, New York, p. 6.
26. 2β; for seasonal prophylaxis of resiratory infection. J. Infect. Dis. 154, 128-133.
27. Nayar, R. and Schroit, A.J. (1989) pH Sensitive Liposomes for the Delivery of Immunomodulators. Liposomes in the Therapy of Infectious Diseases and Cancer, Alan R. Liss Inc., New York, pp. 427-439.
28. Petenazzo, A., Jobe, A., Ikegami, M., Abra, R., Hogue, E. and Mihalko, P. (1989) Clearance of phosphatidylcholine and cholesterol from liposomes, liposomes loaded with metaproterenol and rabbit surfactant from adult rabbit lungs. Am. Rev. Res. Dis. 139, 752-758.
29. Pinto, A.J., Morahan, P.S., Brinton, M., Stewart, D. and Gavin, E. (1990) Comparative therapeutic efficacy of recombinant interferons -α, -β, and -γ against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J. Interfer. Res. 10, 293-298.
30. Poste, G., Kirsh, R., Raz, A., Sone, S., Bucana, C., Fogler, W.E. and Fidler, I.J. (1980) Activation of tumoricidal properties in macrophages by liposome-encapsulated lymphokines: in vitro studies. In: B.H. Tom and H.R. Six (Eds.), Liposomes and Immunobiology, Elsevier North Holland, New York, pp. 93-107.
31. Poste, G., Kirsh, R. and Koestler, T. (1984) The challenge of liposome targeting in vivo. In: G. Gregoriadis (Ed.), Liposome Technology, Vol. 3, CRC Press, Boca Raton, pp. 1-28.
32. Quesada, J.R., Talpaz, M., Rios, A., Kurzrock, R. and Gutterman, J.U. (1986) Clinical toxicity of interferons in cancer patients: a review. J. Clin. Oncol. 4, 234-243.
33. Sone, S., Poste, G. and Fidler, I.J. (1980) Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. J. Immunol. 124, 2197-2202.
34. ten Hagen, T.L.M., van Vianen, W. and Bakker-Woudenberg, A.J.M. (1995) Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-γ alone or combined. J. Infect. Dis. 171, 385-395.
35. Wong, J.P., Cherwonogrodzky, J.W., Di Ninno, V.L., Stadnyk, L.L. and Knodel, M.H. (1992) Liposome potentiation of humoral immune response to lipopolysaccharide and o-polysaccharide antigens of Brucella abortus. Immunology 77, 123-128.
36. Wong, J.P., Stadnyk, L. and Saravolac, E.G. (1994) Enhanced protection against respiratory influenza A infection in mice be liposome-encapsulated antibody. Immunology 81, 280-284.
37. Zhang, X., Alley, E.W., Russel, S.W. and Morrison, D.C. (1994) Necessity and sufficiency of beta interferon for nitric oxide production in mouse peritoneal macrophages. Infect. Immunol. 62, 33-40.